Iteos rises on superior efficacy of lung cancer drug combo vs GSK’s Jemperli alone

iTeos Therapeutics

16/09/2024 10:27

** Shares of cancer drug developer Iteos Therapeutics
 ITOS.O  rise 14.7% at $19.16 premarket
    ** Co says its lung cancer drug, belrestotug, in combination
with GSK's  GSK.L  drug, dostarlimab, showed reduction or
disappearance of tumor in 63.3%-76.7% patients, vs 37.5% in
patients given only GSK's drug
    ** GSK's cancer drug dostarlimab is sold under the brand
name Jemperli
    ** The combo was tested in patients with an advanced kind of
lung cancer called non-small cell lung cancer
    ** Stock up 52.5% YTD, as of last close

 (Reporting by Kashish Tandon in Bengaluru)
 ((Kashish.tandon@thomsonreuters.com))